ARK Genomic Revolution ETF
ARKG
462 hedge funds and large institutions have $1.4B invested in ARK Genomic Revolution ETF in 2021 Q4 according to their latest regulatory filings, with 98 funds opening new positions, 103 increasing their positions, 199 reducing their positions, and 97 closing their positions.
2.85% more ownership
Funds ownership: 24.34% → 27.19% (+2.9%)
1% more first-time investments, than exits
New positions opened: 98 | Existing positions closed: 97
2% less funds holding
Funds holding: 470 → 462 (-8)
14% less funds holding in top 10
Funds holding in top 10: 7 → 6 (-1)
20% less capital invested
Capital invested by funds: $1.75B → $1.4B (-$349M)
48% less repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 199
66% less call options, than puts
Call options by funds: $166M | Put options by funds: $490M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BNP Paribas Financial Markets
Paris,
France
|
+$37.5M |
| 2 |
Goldman Sachs
New York
|
+$33.8M |
| 3 |
Wells Fargo
San Francisco,
California
|
+$19.4M |
| 4 |
CS
Credit Suisse
Zurich,
Switzerland
|
+$11.9M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$9.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Bank of America
Charlotte,
North Carolina
|
-$29.1M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$21.2M |
| 3 |
HF
HRT Financial
New York
|
-$11.5M |
| 4 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$8.53M |
| 5 |
PI
PEAK6 Investments
Chicago,
Illinois
|
-$8.13M |
ARKG Hedge Fund Activity: Q4 2021 in Review
462 of the 6,518 institutional investors tracked by Wall St. Rank reported a position in ARK Genomic Revolution ETF (ARKG) for Q4 2021, worth a combined $1.4B — down 20% from $1.75B a quarter earlier.
Buyers outnumbered sellers: 98 funds opened new ARKG positions and 97 closed out — a net gain of 1 holder — while 103 added to existing stakes and 199 trimmed.
The largest buyer was BNP Paribas Financial Markets, adding an estimated $37.5M. The largest seller was Bank of America, cutting an estimated $29.1M.
- 462 institutional investors held ARK Genomic Revolution ETF (ARKG) as of Q4 2021, down from 470 in Q3 2021.
- Funds reported $1.4B of ARK Genomic Revolution ETF stock for Q4 2021, down 20% quarter-over-quarter.
- 98 funds opened new ARK Genomic Revolution ETF positions in Q4 2021 and 97 closed out, a net change of +1 holder.
- The largest ARK Genomic Revolution ETF buyer in Q4 2021 was BNP Paribas Financial Markets, an estimated $37.5M added.
- The largest ARK Genomic Revolution ETF seller in Q4 2021 was Bank of America, an estimated $29.1M sold.
Based on aggregated 13F filings for Q4 2021.